Institutional Ownership
Entrada Therapeutics Inc
CUSIP 29384C108COMTRDAQ1 2026
13D / 13G Filings
26
Schedule 13D/13G on record
Beneficial Filers
13
Distinct reporting persons
Largest Stake
15.1%
Max % of class reported
Institutional Holders
114
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
26 filings · latest Nov 25, 2025
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Nov 25, 2025 | Tcg Crossover Gp I, LLC | 13G | 5.0% | 1.92M | SEC |
| 2 | Nov 18, 2025 | 5am Ventures V, L.P. | 13D/A | 10.8% | — | SEC |
| 3 | Nov 14, 2025 | T. Rowe Price Associates, Inc. | 13G/A | 0.9% | 360.5K | SEC |
| 4 | Aug 14, 2025 | Janus Henderson Group PLC | 13G/A | 4.0% | 1.52M | SEC |
| 5 | Aug 14, 2025 | T. Rowe Price Associates, Inc. | 13G/A | 6.8% | 2.57M | SEC |
| 6 | May 14, 2025 | Janus Henderson Group PLC | 13G/A | 5.6% | 2.12M | SEC |
| 7 | Feb 14, 2025 | Janus Henderson Group PLC | 13G | 5.6% | 2.08M | SEC |
| 8 | Feb 14, 2025 | Roche Finance Ltd | 13G/A | 6.9% | 2.57M | SEC |
| 9 | Feb 4, 2025 | Blackrock, Inc. | 13G | 5.3% | 1.97M | SEC |
| 10 | Nov 14, 2024 | Price T Rowe Associates Inc /Md/ | 13G/A | 8.2% | 3.05M | SEC |
16 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Entrada Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Baker Bros. Advisors LP | 5.07M | $64.02M |
| 2 | 5am Venture Management, LLC | 4.06M | $51.19M |
| 3 | Blackrock, Inc. | 2.36M | $29.77M |
| 4 | Tcg Crossover Management, LLC | 2.29M | $28.87M |
| 5 | Wellington Management Group LLP | 1.03M | $13.06M |
| 6 | Stepstone Group LP | 761.3K | $9.61M |
| 7 | Geode Capital Management, LLC | 667.3K | $8.42M |
| 8 | State Street Corp | 533.8K | $6.74M |
| 9 | Millennium Management LLC | 519.4K | $6.55M |
| 10 | Jones Hill Capital LP | 374.0K | $4.72M |